At a glance
ClinicalIndex Comparison Record- ✓Age 18 to 80 years
- ✓History of refractory or unexplained chronic cough
- ✓Chest radiograph or CT scan showing no significant abnormality contributing to chronic cough
- ✓Agreement to discontinue antitussive medications for trial duration
- ✕Current smoker or recent cessation, or history of >20 pack-years smoking
- ✕Significant cardiovascular disease or clinically significant cardiac rhythm/conduction abnormalities
- ✕Significant hepatic disease or condition interfering with drug absorption, distribution, metabolism, or excretion
- ✕Malignancy within 5 years of screening (except treated basal/squamous cell skin cancers or cervical carcinoma in situ)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects With Chronic Cough
In Brief
A Phase 2 clinical trial evaluating ADX-629 and Placebo for Chronic Cough. Completed, enrolled 51 participants across 14 sites.
Detailed Summary
A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Chronic Cough
Study Details
Timeline
Interventions
Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.